Ivan Formentini

Ivan Formentini

Company: Novo Nordisk

Job title: Scientific Vice President & Head of Translational Science

Seminars:

Chair’s closing remarks 5:00 pm

Read more

day: Day Two

Leveraging In Vivo & In Vitro Models to Predict Target Engagement & Understand Disease Mechanisms 10:45 am

Read more

day: Track 1 - Day 2 AM

Panel Discussion: Identifying & Validating a Novel Therapy to Complement SGLT2 Inhibitors 9:30 am

Defining the next wave of therapeutics discovery after SGLT2i to improve clinical outcomes Measuring incremental benefit of novel therapeutics in addition to SGLT2 inhibitors Optimizing a smart preclinical screening platform to monitor efficacy in addition to standard of care Considering innovative trial design and untraditional endpoints to demonstrate efficacy and meet regulatory requirementsRead more

day: Day Two

Chair’s Opening Remarks 8:25 am

Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.